Eli Lilly Becomes First Drugmaker to Win Approval for GLP-1 Weight-Loss Pill in China

Eli Lilly has become the first pharmaceutical manufacturer to receive approval in China for a GLP-1 class weight-loss pill. According to a Reuters report, the approval is seen as a significant step in the company's global expansion in obesity and diabetes treatment. GLP-1 receptor agonists are known for their effects on blood sugar regulation and appetite control. The approval of a pill form in this class in the Chinese market could increase access to non-injectable treatment options. With this approval, Eli Lilly is expected to gain a competitive advantage in China's weight management market. The company continues its investments in the GLP-1 field on a global scale. The high prevalence of obesity and diabetes in China stands out as a factor supporting demand for such treatments. However, the commercial effects of the approval and market share dynamics are not yet clear. This is not investment advice.

📊 LLY — Piyasa Yorumu

▲ up · 62%

Eli Lilly's approval of its GLP-1 weight-loss pill in China is a positive catalyst that strengthens the company's position in the global obesity market. The price rose 5.3% in 24 hours and is trading above the SMA20 and SMA50; MACD is above the signal line and RSI at 66.7 is approaching overbought territory. Momentum is likely to continue in the short term, but the RSI level indicates limited room for further gains. The news may be largely priced in; a moderately positive trend is expected over the 1-3 day outlook. Nevertheless, caution is warranted against profit-taking.

RSI 14

66.8

MACD

9.69

24h Δ

5.34%

📊 GOOGL — Piyasa Yorumu

■ neutral · 20%

The news headline concerns Eli Lilly and the China GLP-1 market and has no direct connection to GOOGL. Therefore, no significant short-term directional impact on GOOGL is expected. Technical indicators show the price above SMA20 and SMA50, RSI at 59 in neutral-positive territory, and MACD above its signal, indicating a mildly positive trend. However, since the news is not a stock-specific catalyst, the directional call remains weak. In the short term, maintaining the current technical trend and no news-driven deviation is more likely.

RSI 14

59.2

MACD

1.65

24h Δ

2.71%

Canlı Grafikler